Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 October 2018 | Story UFS | Photo Rulanzen Martin
Prof Charles Ngwena is a former professor in the UFS Department
Prof Charles Ngwena is a former professor in the UFS Department of Constitutional Law and Legal Philosophy in the Faculty of Law.

The meaning of race, culture and sexism in Africa takes a different tone than it does in the West. The West has always tried to create an identity for Africa, but the real question remains: “What does it mean to be an African?’ 

“My aim with this book was to see how discourse is formed and what it means when you say the word ‘African’, which is meaningless. You have to look back to understand how that was created,” said Prof Charles Ngwena.

Prof Ngwena’s new book, asks the critical question,‘What is Africanness?’ Fully titled, What is Africanness? Contesting nativism in race, culture and sexualities is a timely contribution to contemporary South African debates on issues of decolonisation, race, ethnicity, nation building and belonging.

Identity formation a crucial element

“The book speaks directly to African cultural heritage and deconstructs a Western-imposed and homogenising framework for understanding Africanness,” said Dr Nadine Lake from the Centre for Gender and Africa Studies (CGAS) at the University of the Free State (UFS).

Prof Ngwena foregrounds the importance of intersectionality when approaching issues of race, culture and sexuality and writes: “Genericness is ineluctably homogenising. It can serve to obscure heterogeneities among women, pre-empting the need to explore the implications of differences among women in feminist theory and praxis.

“Identity is being and becoming. It is always changing. What young people think of identity is not the same way their grandparents thought about it,” said Prof Ngwena. He added that his contribution through this book was to underlay identity formation.

The book, published by Pretoria University Law Press (PULP), was launched in a joint venture by CGAS, the Centre for Human Rights at the University of Pretoria on Tuesday 11 September 2018 at the UFS.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept